About: David P. Steensma

Facets (new session)
Description
Metadata
Settings
- owl:sameAs
- Inference Rule:

About: David P. Steensma Goto Sponge NotDistinct Permalink

An Entity of Type : wikibase:Item, within Data Space : wikidata.demo.openlinksw.com associated with source document(s)

researcher

Attributes	Values
rdf:type	Item
description	forskare (sv) ikertzailea (eu) researcher (en) 연구원 (ko) ricercatore (it) গবেষক (bn) 研究者 (ja) ഗവേഷകൻ (ml) wetenschapper (nl) дослідник (uk) эрдэмтэн (mn) वैज्ञानिक (hi) باحت (ary) изилдөөчү (ky) 研究者 (zh) հետազոտող (hy) hulumtues (sq)
rdfs:label	David P Steensma (de) David P Steensma (fr) David P Steensma (nl) David P Steensma (sl) David P. Steensma (en) David P. Steensma (es) David P. Steensma (sv)
skos:prefLabel	David P Steensma (de) David P Steensma (fr) David P Steensma (nl) David P Steensma (sl) David P. Steensma (en) David P. Steensma (es) David P. Steensma (sv)
name	David P Steensma (de) David P Steensma (fr) David P Steensma (nl) David P Steensma (sl) David P. Steensma (en) David P. Steensma (es) David P. Steensma (sv)
Scopus author ID	wds:Q42586417-CFC9DB67-BE20-4569-81EC-B9A4D1A62683
Scopus author ID	7005639226
given name	wds:Q42586417-6A7555F9-D64F-496A-9EBC-D89C79F13761
given name	David
instance of	wds:Q42586417-669FB8E7-DE55-48E2-A32B-BBDE615E5A88
instance of	Homo sapiens
skos:altLabel	David Steensma (en)
occupation	wds:Q42586417-8A1E9085-5F32-4E9A-8594-11243C98C882
employer	wds:Q42586417-02CC521C-543B-42E0-8708-916035E2AE62 wds:Q42586417-1DBA1FC9-D00D-4783-AC80-67A1DCCF14EE
sex or gender	wds:Q42586417-4DE93C61-6C69-4A55-A88F-10556CCFB8F8
ISNI	wds:Q42586417-69B0D6FD-DD9C-49B3-ABDD-ED0B7FF3B62B
VIAF ID	wds:Q42586417-A3E9921A-60F8-43CD-B102-EC1091B3DD0D
GND ID	wds:Q42586417-e7580445-963f-4795-96b8-82a266afe719
Library of Congress authority ID	wds:Q42586417-BD5FD4CE-E1ED-42F9-AD94-60C63997CCDD
IdRef ID	wds:Q42586417-765BF0D1-79B3-46ED-94AE-5D5133DA3F44
PLWABN ID	wds:Q42586417-A8F60FA9-362F-4BB4-AE3C-23BF3C56EBB8
family name	wds:Q42586417-7A5D6F47-CFF7-45AC-BB0C-1B75CD0A9D52
WorldCat Identities ID (superseded)	wds:Q42586417-1D51ABA6-EDB7-4A57-9A9E-57D092AD7BDB
National Library of Israel J9U ID	wds:Q42586417-90351E38-6FBE-4453-9174-4A56E2F6C939
official website	wds:Q42586417-8D011B34-54FE-47B8-A540-490E61D7F8B4
VIAF ID	http://viaf.org/viaf/315218942
GND ID	https://d-nb.info/gnd/1207777749
Library of Congress authority ID	http://id.loc.gov/authorities/names/n2008183464
IdRef ID	http://www.idref.fr/142646725/id
occupation	researcher
employer	Mayo Clinic Dana–Farber Cancer Institute
sex or gender	male
ISNI	0000000040212826
VIAF ID	315218942
GND ID	1207777749
Library of Congress authority ID	n2008183464
IdRef ID	142646725
PLWABN ID	9810656729605606
family name	Steensma
WorldCat Identities ID (superseded)	lccn-n2008183464
National Library of Israel J9U ID	987008196486505171
official website	http://www.dfhcc.harvard.edu/membership/profile/member/1667/0/?PHPSESSID=d56053404da6a7fef66de660382e4246
ORCID iD	wds:Q42586417-2A6FA294-C77A-4298-822C-F6828C312FC5
ORCID iD	https://orcid.org/0000-0001-5130-9284
ORCID iD	0000-0001-5130-9284
is about of	https://www.wikidata.org/wiki/Special:EntityData/Q42586417
is author of	Niche-based screening identifies small-molecule inhibitors of leukemia stem cells Mutations in the chromatin-associated protein ATRX. JAK2 V617F is a rare finding in de novo acute myeloid leukemia, but STAT3 activation is common and remains unexplained Hematologic and cytogenetic response to lenalidomide monotherapy in acute myeloid leukemia arising from JAK2(V617F) positive, del(5)(q13q33) myelodysplastic syndrome Physician-poet William Carlos Williams--"no ideas but in things". Phase III, randomized study of the effects of parenteral iron, oral iron, or no iron supplementation on the erythropoietic response to darbepoetin alfa for patients with chemotherapy-associated anemia Erythropoietin or Darbepoetin for patients with cancer - meta-analysis based on individual patient data Phase III study of two different dosing schedules of erythropoietin in anemic patients with cancer The JAK2 V617F activating tyrosine kinase mutation is an infrequent event in both "atypical" myeloproliferative disorders and myelodysplastic syndromes Phase I dose escalation study of bortezomib in combination with lenalidomide in patients with myelodysplastic syndromes (MDS) and acute myeloid leukemia (AML). New strategies in myelodysplastic syndromes: application of molecular diagnostics to clinical practice A phase 2 trial of combination low-dose thalidomide and prednisone for the treatment of myelofibrosis with myeloid metaplasia International working group for myelofibrosis research and treatment response assessment and long-term follow-up of 50 myelofibrosis patients treated with thalidomide-prednisone based regimens. Etanercept, a soluble tumor necrosis factor receptor, palliates constitutional symptoms in patients with myelofibrosis with myeloid metaplasia: results of a pilot study. On the TRAIL of a new therapy for leukemia. TET2 mutations predict response to hypomethylating agents in myelodysplastic syndrome patients Outcome of patients with low-risk and intermediate-1-risk myelodysplastic syndrome after hypomethylating agent failure: a report on behalf of the MDS Clinical Research Consortium Validation of a prognostic model and the impact of mutations in patients with lower-risk myelodysplastic syndromes

Faceted Search & Find service v1.16.117 as of May 05 2024

Alternative Linked Data Documents: ODE Content Formats:

RDF

ODATA

Microdata

About

OpenLink Virtuoso version 07.20.3239 as of May 5 2024, on Linux (x86_64-centos_6-linux-gnu), Single-Server Edition (378 GB total memory, 193 GB memory in use)
Data on this page belongs to its respective rights holders.
Virtuoso Faceted Browser Copyright © 2009-2024 OpenLink Software